Life Sciences

  • July 09, 2026

    Sam's Club Reaches Deal With Ex-Worker In Miscarriage Suit

    Sam's Club and a former employee who alleged she suffered a miscarriage after the retailer failed to accommodate work restrictions related to her attempt to become pregnant through in vitro fertilization have reached a settlement.

  • July 08, 2026

    Jazz Patent Suit Over Xyrem Survives Dismissal In NJ

    A New Jersey federal judge has refused to let generic-drug company Tris Pharma Inc. escape a suit claiming its attempt to sell a competing version of Jazz Pharmaceuticals' narcolepsy drug Xyrem infringes a series of patents.

  • July 08, 2026

    AstraZeneca Employee Traded On Icosavax Deal, SEC Says

    The U.S. Securities and Exchange Commission on Wednesday accused a former AstraZeneca Pharmaceuticals LP employee of using nonpublic information to trade ahead of the company's $1.1 billion acquisition of vaccine design company Icosavax Inc., yielding approximately $10,000 in illicit gains.

  • July 08, 2026

    Pa. Superior Court Upholds J&J Win In Talc Cancer Suit

    The Pennsylvania Superior Court on Tuesday upheld a 2025 verdict clearing Johnson & Johnson of liability in a suit alleging that using talc caused a woman's fatal mesothelioma, finding that a lower court didn't err by clarifying the jury's instructions after jurors awarded $22 million in punitive damages.

  • July 08, 2026

    Formula-Maker Sued After Recall And Reports Of Sick Infants

    Infant formula manufacturer Nara Organics Inc. sold milk-based powder that had to be recalled after federal regulators learned that multiple infants who had consumed the product were hospitalized with life-threatening botulism, according to a proposed class action filed Wednesday in New York federal court.

  • July 08, 2026

    PBMs Fight Bid To Add Pharmacy Group To Price-Fixing Suit

    Two pharmacy benefit managers have told a Michigan federal judge that a trade association for small pharmacies should not be allowed to intervene in a price-fixing lawsuit brought by the state's attorney general.

  • July 08, 2026

    Sheppard Adds Transactional, IP Attys In Chicago And San Diego

    Sheppard announced Wednesday that the firm has added an experienced intellectual property attorney focused on life sciences as a San Diego area-based partner, a day after announcing the addition of two Chicago-based transactional partners.

  • July 08, 2026

    Handa, Intas Face Patent Suits Over Exelixis Cancer Drug

    Handa Pharmaceuticals and Intas Pharmaceuticals are wrongly trying to bring to market drugs that would compete with Exelixis Inc.'s blockbuster cancer pill Cabometyx before patents on the medication expire, according to a new lawsuit in Delaware federal court.

  • July 08, 2026

    Biggest Rulings For Patent Attys In 2026: A Midyear Report

    The U.S. Supreme Court clarified the pleading standard for induced infringement of skinny labels, and the Federal Circuit opened the door to increased damages for patent owners. Here's what you need to know about these patent cases and other major decisions from the beginning of 2026.

  • July 07, 2026

    2 Ex-Telehealth Execs Sentenced For $100M Adderall Scheme

    A California federal judge on Tuesday sentenced two former executives of a telehealth company who were convicted of operating a $100 million scheme to illegally distribute Adderall over the internet, fining them $1 million each and giving the founder six years in prison.

  • July 07, 2026

    Illinois Cases To Watch In 2026: Midyear Report

    Mead Johnson is set to go to trial this summer in the first case to make it to a jury in multidistrict litigation claiming baby formula caused a serious gut illness in premature infants, while the U.S. attorney's office in Chicago is facing a possible sanctions hearing over prosecutorial misconduct allegations in two Illinois cases on attorneys' radar for the rest of the year.

  • July 07, 2026

    Regeneron Ducks Amgen's Eylea Antitrust Counterclaims

    A West Virginia federal judge dismissed key counterclaims and defenses Tuesday that Amgen had raised against Regeneron's patent infringement lawsuit targeting bids by multiple would-be rivals to produce biosimilar versions of eye medication Eylea, preserving only arguments that Regeneron waited too long to pursue the patent.

  • July 07, 2026

    CEO Cops To Conspiracy In BigLaw Insider Trading Case

    A Dubai-based CEO and trader has pled guilty in Massachusetts federal court to charges that he worked with a former BigLaw associate and others to carry out a far-reaching insider trading scheme.

  • July 07, 2026

    Align's Invisalign Patents Are Infringed But Invalid, Jury Finds

    A Texas federal jury has found that claims in four patents Invisalign maker Align Technology Inc. asserted against orthodontics company ClearCorrect were invalid, but the jurors also rejected ClearCorrect's antitrust claims against Align.

  • July 07, 2026

    Unstable Ex-Pfizer Office Spurs Evacuations In Manhattan

    The reported instability of pharmaceutical giant Pfizer's former New York City office headquarters, which is undergoing a conversion into residential units, led to the evacuations of multiple nearby buildings in Midtown Manhattan Tuesday.

  • July 07, 2026

    23andMe's $47M Data Breach Deal Gets Bankruptcy Court OK

    A Missouri bankruptcy judge entered an order Tuesday authorizing a $46.7 million settlement between the plan administration trust created under the Chapter 11 plan of DNA-testing company 23andMe and data breach claimants, finding the deal is fair and equitable. 

  • July 07, 2026

    Mayo Sacked Research Director For Flagging Flaws, Suit Says

    Mayo Clinic retaliated against and eventually terminated its director of research operations after she brought up concerns about security, safety and privacy regarding the medical center's use of artificial intelligence and other protocols, according to a lawsuit filed in Minnesota federal court on Monday.

  • July 07, 2026

    P&G Brushes Off Harm Of Toothpaste Ingredient, Suit Claims

    Procter & Gamble misleads consumers of its Crest Pro-Health toothpastes by failing to convey that the ingredient sodium lauryl sulfate can damage gum and mouth tissue and trigger inflammation — "the very conditions" the products are marketed as mitigating, a proposed class action alleges in California federal court.

  • July 07, 2026

    Groups Tell 4th Circ. Not To Let Sandoz 'Relitigate' Enbrel

    Pharmaceutical groups and the Washington Legal Foundation backed Amgen in amicus briefs Monday urging the Fourth Circuit not to revive Sandoz's antitrust claims, arguing that if Sandoz wanted to litigate blocked biosimilar competition to Enbrel, it needed to do so when Amgen sued it for patent infringement.

  • July 07, 2026

    5th Circ. Again Nixes Challenge To La. 340B Drug Delivery Law

    A Fifth Circuit panel doubled down on its decision to uphold a Louisiana law prohibiting drug manufacturers from blocking contracts between pharmacies and providers in the federal 340B drug discount program, reiterating that conclusion upon rehearing but this time allowing intervention by an advocacy group.

  • July 07, 2026

    Fed. Circ. Won't Revive Dental Patent Claims In Align Feud

    The Federal Circuit on Tuesday said it won't bring back claims in a pair of dental arch image analysis patents their owner accused Invisalign maker Align Technology Inc. of infringing, backing a lower court's finding that they were invalid.

  • July 07, 2026

    Longtime Goodwin Procter IP Lawyer Moves To Pillsbury In DC

    A career Goodwin Procter LLP lawyer, who spent nearly two decades at that firm working on high-stakes intellectual property disputes, has joined Pillsbury Winthrop Shaw Pittman LLP's Washington, D.C., office.

  • July 06, 2026

    CVS To Pay $36.5M To Settle States' Insulin FCA Suits

    CVS has agreed to shell out $36.5 million to put to rest a handful of False Claims Act suits from states and the federal government, which allege the pharmacy chain submitted fraudulent Medicaid claims after giving patients more insulin than they were prescribed and lying about refill timelines.

  • July 06, 2026

    3 Firms Guide Vertex's $10B Buy Of Crinetics Pharmaceuticals

    Kirkland & Ellis LLP is advising Vertex Pharmaceuticals Inc. in its $10 billion acquisition of Crinetics Pharmaceuticals Inc., which is being represented by both Paul Weiss Rifkind Wharton & Garrison LLP and Morrison Foerster LLP, according to an announcement made Monday.

  • July 06, 2026

    5,000 Pharmacies Accuse Prime Therapeutics Of Price-Fixing

    Nearly 5,000 pharmacies accuse Prime Therapeutics LLC of entering into an unlawful price-fixing agreement with rival pharmacy benefit manager Express Scripts Inc. to deflate pharmacies' reimbursement rates and inflate their fees, according to a new lawsuit filed in Seattle federal court.

Expert Analysis

  • How To Gear Up For Trump's Pharma Tariffs

    Author Photo

    President Donald Trump's proclamation establishing tariffs on certain pharmaceutical products holds a few areas of ambiguity that companies should review and prepare for before the tariffs come into effect later this year, say attorneys at Arnold & Porter.

  • How The Coming Months Will Shape State Drug Price Boards

    Author Photo

    The future of state prescription drug affordability boards may be determined in the next few months, between an upcoming court decision in a challenge against state authority to set drug prices, and pending state decisions about whether to use federal Medicare maximum fair prices as reference, say Michael Kolber, Steven Chen and Kelechi Ezealaji at Manatt.

  • High Court 'Skinny Label' Case Will Matter To Tech Litigators

    Author Photo

    Hikma v. Amarin, set for oral argument in the U.S. Supreme Court on Wednesday, has potential to affect not just generic drug label-based evidence in patent cases, but also how technology inducement cases are presented and proven, says attorney Abdul Abdullahi.

  • How Food, Beverage Claims May Preview Cosmetic Litigation

    Author Photo

    Class action litigation targeting cosmetics and personal care products is accelerating, with a playbook that comes from the food and beverage industry — and the defenses that succeeded, and failed, in past class actions offer a critical road map for beauty and personal care brands, say attorneys at Crowell.

  • Court's HRSA Policy Reversal Leaves 340B Rules Murky

    Author Photo

    A D.C. federal court's recent decision in Premier v. U.S. Department of Health limits the Health Resources and Services Administration's ability to enforce long-standing Section 340B interpretations through subregulatory guidance, leaving open core statutory questions about purchasing models, inventory classification and program oversight, says Martha Cramer at Hooper Lundy.

  • Series

    Officiating Football Makes Me A Better Lawyer

    Author Photo

    Though they may seem to have little in common, officiating football has sharpened many of the same skills that define effective lawyering in management-side labor and employment: preparation, judgment, composure, credibility and ability to make difficult decisions in real time, says Josh Nadreau at Fisher Phillips.

  • Fresenius Ruling May Shift Anti-Kickback Enforcement

    Author Photo

    The Ninth Circuit's recent decision in Fresenius v. Bonta suggests that businesses have a First Amendment right to donate to certain charities, even if those donations are motivated by economic self-interest, potentially calling into question years of Anti-Kickback Statute proceedings against pharmaceutical manufacturers for making similar donations, says Jonah Knobler at Patterson Belknap.

  • Written Consent Ruling May Signal Change For Telemarketing

    Author Photo

    The Fifth Circuit's ruling in Bradford v. Sovereign Pest Control is a takedown of the Federal Communications Commission's prior express written consent regulation, and because Loper Bright empowers courts to disregard agency interpretations, Telephone Consumer Protection Act litigants now have an opportunity to challenge previously settled FCC regulations, orders and interpretations, say attorneys at Manatt.

  • Series

    Law School's Missed Lessons: How To Draft Pleadings

    Author Photo

    Most law school graduates step into their first jobs without ever having drafted a complaint, answer, motion or other type of pleading, but that gap can be closed by understanding the strategy embedded in every filing, writing with clarity and purpose, and seeking feedback at every step, says Eric Yakaitis at Haug Barron.

  • At The Fed. Circ., Means-Plus-Function Is Not Quite Dead

    Author Photo

    Recent Federal Circuit opinions confirm that means-plus-function claims continue to be drafted, issued, litigated and even infringed — but minding the restrictions imposed over the years by courts and statute requires three steps, says Jay Yates at Patterson & Sheridan.

  • E-Discovery Quarterly: Recent Rulings On ESI Control

    Author Photo

    Several recent federal court decisions have perpetuated a split over what constitutes “control” of electronically stored information — with judges divided on whether the standard should turn on a party's legal right or practical ability to obtain the information, say attorneys at Sidley.

  • Opinion

    USPTO Should Let Inventors Valuate Patents In Prosecution

    Author Photo

    By building patent valuation into the application process, rather than waiting until potential litigation years down the line, the U.S. Patent and Trademark Office would streamline the process for inventors protecting and enforcing their patents, says John Powers at Powers IP.

  • 2 Discovery Rulings Break With Heppner On AI Privilege Issue

    Author Photo

    While a New York federal court’s recent ruling in U.S. v. Heppner suggests that some litigants’ communications with AI tools are discoverable, two other recent federal court decisions demonstrate that such interactions generally qualify for work-product protection under the Federal Rules of Civil Procedure, says Joshua Dunn at Brown Rudnick.

  • Series

    Isshin-Ryu Karate Makes Me A Better Lawyer

    Author Photo

    My involvement in martial arts, specifically Isshin-ryu, which has principles rooted in the eight codes of karate, has been one of the most foundational in the development of my personality, and particularly my approach to challenges — including in my practice of law, says Kaitlyn Stone at Barnes & Thornburg.

  • Microplastics On Water Contaminant List Could Spur Claims

    Author Photo

    The U.S. Environmental Protection Agency's proposal to include microplastics in its draft sixth Contaminant Candidate List under the Safe Drinking Water Act could influence consumer fraud claims and enforcement by state attorneys general, as well as claims against manufacturers from entities facing regulatory compliance costs, says Arie Feltman-Frank at Jenner & Block.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.